Skip to main content
. 2018 Summer;17(3):1093–1098.

Table 2.

Indication for injection of Bevacizumab (Avastin).

Indication Number of patients
CSME 221 (61.55%)
PDR with VH 23 (6.40%)
CNV 59 (16.43%)
CRVO 28 (7.79%)
BRVO 23 (6.40%)
NVG 4 (1.11%)
Parafoveal Telangiectasia 1 (0.27%)

CSME = Clinically Significant Macular Edema, PDR = Proliferative Diabetic Retinopathy, CNV = Choroidal neovascularization, CRVO = Central Retinal Vein Occlusion, BRVO = Branch Retinal Vein Occlusion, NVG = Neovascular Glaucoma